Kiniksa Pharmaceuticals International (KNSA) Other Non Operating Income (2022 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Other Non Operating Income for 5 consecutive years, with $4.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non Operating Income rose 45.42% year-over-year to $4.0 million; the trailing twelve-month figure through Jun 2026 stood at $14.0 million (up 43.07% YoY), and the FY2025 full-year result was $11.6 million, up 23.07% from the prior year.
• Other Non Operating Income grew to $4.0 million in Q2 2026 per KNSA's latest filing, from $3.4 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $4.0 million in Q2 2026 and bottomed at $34000.0 in Q1 2022.
• Historically, Other Non Operating Income has averaged $2.1 million across 5 years, with a median of $2.3 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Other Non Operating Income surged 5288.24% in 2023, then decreased 2.07% in 2024.
• Over 5 years, Other Non Operating Income stood at $794000.0 in 2022, then jumped by 198.36% to $2.4 million in 2023, then decreased by 2.07% to $2.3 million in 2024, then soared by 50.91% to $3.5 million in 2025, then grew by 12.85% to $4.0 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $4.0 million, $3.4 million, and $3.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.